Akman Demir, GulsenTurkoglu, RecaiSaip, SabahattinYuceyar, NurEfendi, HusnuTuran, Omer FarukKocer, Belgin2021-05-032021-05-0320191300-06671309-4866https://doi.org/10.5152/npa.2017.20515https://hdl.handle.net/11454/70522Boz, Cavit/0000-0003-0956-3304; TERZI, Murat/0000-0002-3586-9115; YUCEYAR, NUR/0000-0003-4590-6423Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated. Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.en10.5152/npa.2017.20515info:eu-repo/semantics/openAccessMultiple sclerosisfingolimodpatient satisfactionquality of lifeArticle564253257WOS:00051020760000531903032Q3N/A